SCHEMBL71908

SCHEMBL71908

CC(NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.63
PLA2G10 O15496 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
SLC6A5 Q9Y345 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPK1 P28482 1/20 0.50
PLA2G2C Q5R387 1/20 0.49
TSHR P16473 4/20 0.48
LMNA P02545 1/20 0.48
NFKB1 P19838 1/20 0.48
PMP22 Q01453 1/20 0.48
ALDH1A1 P00352 3/20 0.47
MAPT P10636 1/20 0.47
PPARG P37231 4/20 0.45
PPARD Q03181 4/20 0.45
PPARA Q07869 4/20 0.45
GPR84 Q9NQS5 3/20 0.45
HDAC11 Q96DB2 3/20 0.45
TDP1 Q9NUW8 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15850011 1.00 FAAH (0.63) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL15680128 1.00 FAAH (0.63) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL15680096 1.00 FAAH (0.63) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL14331545 1.00 FAAH (0.63) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL12295267 1.00 FAAH (0.63) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL15602821 0.98 FAAH (0.60) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL15602822 0.98 FAAH (0.60) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL4572557 0.94 FAAH (0.56) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL30838580 0.94 FAAH (0.69) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL30838579 0.94 FAAH (0.69) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020146521-A2 RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE Arrowhead Pharmaceuticals, Inc. (US) 2020-07-16 WO disclosed
US-8765130-B2 Antagonistic DR3 ligands NOVO NORDISK A/S (DK) 2014-07-01 US disclosed
US-8129343-B2 Acylated GLP-1 compounds NOVO NORDISK A/S (DK) 2012-03-06 US disclosed
US-8129343-B2 Acylated GLP-1 compounds NOVO NORDISK A/S (DK) 2012-03-06 US disclosed
US-20090156478-A1 Acylated GLP-1 Compounds NOVO NORDISK A/S (DK) 2009-06-18 US disclosed
US-20090156478-A1 Acylated GLP-1 Compounds NOVO NORDISK A/S (DK) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156478-A1 Acylated GLP-1 Compounds GLP1R, GIPR, GCGR FAAH 193/4885PLA2G10 604/4885SMN1; SMN2 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.